-

FairJourney Biologics Expands Into New Facilities in Porto, Portugal

Newly purpose-built research center supports rapid expansion of Company

PORTO, Portugal--(BUSINESS WIRE)--FairJourney Biologics S.A. (FJB), leader in the discovery and optimization of antibodies, today announced it has relocated into a larger, newly purpose-built research center in Porto, Portugal. The new premises support the Company’s expansion and plans for further growth.

FairJourney Biologics now occupies over 200,000 square feet, with the new premises containing 140 fully equipped laboratories, meeting rooms and social areas, as well as green spaces and leisure areas to promote employee well-being. The state-of-the-art facility will house more projects and industry leading equipment, enabling the Company to support more clients and carry out world-class research into antibody-based drugs.

António Parada, CEO of FairJourney Biologics commented: “Our relocation into a new research center demonstrates our trajectory toward further growth. The move is an exciting development for the Company and gives us the flexibility to support more projects and continue to expand our market-leading antibody library.”

Contacts

Zyme Communications
Lorna Cuddon
lorna.cuddon@zymecommunications.com
Tel: +44(0)7811 996 942

FairJourney Biologics


Release Versions

Contacts

Zyme Communications
Lorna Cuddon
lorna.cuddon@zymecommunications.com
Tel: +44(0)7811 996 942

More News From FairJourney Biologics

FairJourney Bio Launches Cryo-EM Services With Advanced Laboratories in San Diego, USA

PORTO, Portugal and SAN DIEGO, Calif.--(BUSINESS WIRE)--FairJourney Bio (FJBio), a leading global provider of antibody discovery and development services, today announced the expansion of its portfolio with the launch of state-of-the-art cryo-electron microscopy (cryo-EM) services, supported through the Company’s advanced laboratories in San Diego, CA. This strategic addition strengthens FJBio’s position as a trusted partner for pharmaceutical and biotechnology companies worldwide by providing...

FairJourney Bio to present at J.P. Morgan 2026 Healthcare Conference

PORTO, Portugal--(BUSINESS WIRE)--FairJourney Bio (FJBio), a global leader in antibody discovery and development, announced today that its Chief Executive Officer, Dr. Werner Lanthaler, will present at the J.P. Morgan 2026 Healthcare Conference, taking place from January 12 – 15, 2026 in San Francisco, CA. With more than a decade of expertise, FJBio has supported over 250 clients across Pharma, Biotech and Academia and contributed to more than 19 antibodies advancing to clinical stage developme...

FairJourney Biologics Appoints Dr. Werner Lanthaler as Chief Executive Officer

PORTO, Portugal--(BUSINESS WIRE)--FairJourney Biologics S.A. (FJBio), a global leader in antibody discovery and development, today announced that Dr. Werner Lanthaler has been appointed Chief Executive Officer (CEO) to further strengthen its global position as an integrated powerhouse of efficient antibody discovery and development. After nearly 14 years leading FairJourney Biologics, Founder António Parada will focus on driving FJBio’s innovation strategy on the Supervisory Board. Dr. Werner L...
Back to Newsroom